84 results
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
2 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
6:03am
for the three months ended March 31, 2024 and March 31, 2023, respectively.
R&D expenses, inclusive of share-based compensation expense, were $5.6 million … to ceasing development of our AUR200 and AUR300 programs.
Non-cash R&D share-based compensation expense included within R&D expense was $(2.2
8-K
EX-99.1
8pga61l5fjjio
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
8-K
EX-99.1
tfe6l8dxhwazms1ihvyr
2 Nov 23
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
6:01am
8-K
EX-99.1
pco7qt6jgh0uk102w03
21 Aug 23
Dr. Daniel G. Billen appointed Chair of the Board of Directors
4:11pm
8-K
EX-99.1
vqii1ja6dmep f8bhomr
3 Aug 23
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
6:03am
8-K
EX-99.1
35riczts
4 May 23
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
6:06am
DEFA14A
mdus rzvmphlyhke4s
28 Apr 23
Additional proxy soliciting materials
4:03pm
PX14A6G
mujvf8sa0
26 Apr 23
Letter to shareholders
10:20am
8-K
EX-99.1
imd o2digdzv
3 Nov 22
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
6:04am
8-K
EX-99.1
6qs9gloj7gllv
4 Aug 22
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
6:07am